Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.
Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS. Dybul M, et al. Among authors: hertogs k. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15161-6. doi: 10.1073/pnas.261568398. Epub 2001 Dec 4. Proc Natl Acad Sci U S A. 2001. PMID: 11734634 Free PMC article.
Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.
Dybul M, Chun TW, Ward DJ, Hertogs K, Larder B, Fox CH, Orenstein JM, Baird BF, Li Y, Green LG, Engel D, Liu S, Mican JM, Fauci AS. Dybul M, et al. Among authors: hertogs k. J Infect Dis. 2000 Apr;181(4):1273-9. doi: 10.1086/315407. J Infect Dis. 2000. PMID: 10836864 Clinical Trial.
Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.
Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS. Dybul M, et al. Among authors: hertogs k. J Infect Dis. 2003 Aug 1;188(3):388-96. doi: 10.1086/376535. Epub 2003 Jul 10. J Infect Dis. 2003. PMID: 12870120 Clinical Trial.
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.
Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA. Shafer RW, et al. Among authors: hertogs k. J Clin Microbiol. 2001 Apr;39(4):1522-9. doi: 10.1128/JCM.39.4.1522-1529.2001. J Clin Microbiol. 2001. PMID: 11283081 Free PMC article.
Resistance to antiretroviral therapy among patients in Uganda.
Weidle PJ, Kityo CM, Mugyenyi P, Downing R, Kebba A, Pieniazek D, Respess R, Hertogs K, De Vroey V, Dehertogh P, Bloor S, Larder B, Lackritz E. Weidle PJ, et al. Among authors: hertogs k. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):495-500. doi: 10.1097/00126334-200104150-00017. J Acquir Immune Defic Syndr. 2001. PMID: 11391172
95 results